Clinical Trials Logo

Beta Thalassemia Major clinical trials

View clinical trials related to Beta Thalassemia Major.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT03276455 Not yet recruiting - Clinical trials for Beta Thalassemia Major

Gene Therapy for Beta-Thalassemia Major Using Autologous Hematopoietic Stem Cell Genetically Modified

Start date: September 15, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single group, open label study in 10 subjects who are 8 years of age or older with beta-thalassemia major. The objective of this study is to evaluate the safety and efficacy of autologous hematopoietic stem cell transduced with lentiviral vector for the treatment of beta-thalassemia major.

NCT ID: NCT02173951 Not yet recruiting - Clinical trials for Beta Thalassemia Major

An Algorithm to Start Iron Chelation in Minimally Transfused Young Beta-thalassemia Major Patients

Start date: July 2014
Phase: Phase 2/Phase 3
Study type: Interventional

A prospective randomized study on Safety, Tolerability and Efficacy of oral Low dose DFP (50 mg/kg/day) in minimally transfused B-TM after 5 transfusions when SF reaches 500 ng/m and with either appearance of LPI > 0.2 or TSAT reaches 50% compared with non treatment arm. So the aim of this study: 1. To determine the time as well as amount of transfused iron ( calculated in mg iron/kg ) which lead to Serum ferritin reaches 500 ng /ml and LPI appearance >0.2 as well as TSAT reaches 50 % . 2. Tolerability and safety of early low dose DFP 50mg/kg and effectiveness to postpone or prevent SF from reaching 1000 ng/ml or LPI >0.6 or TSAT >70% in comparison to patients not starting chelation therapy 3. Determine adverse events whether drug or non drug related

NCT ID: NCT01511848 Not yet recruiting - Sickle Cell Disease Clinical Trials

Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload

Start date: February 2012
Phase: Phase 2/Phase 3
Study type: Interventional

Interventional Allocation: Randomized Endpoint Classification: Safety/Efficacy Study of combined chelation therapy Masking: Open Label Primary Purpose: Treatment of transfusional iron overload Primary Outcome Measures: • The primary outcome measure is to assess efficacy in lowering serum ferritin level(the change in serum ferritin compared to baseline) with combining DFP and deferasirox compared to combined DFP and DFO in conditions with severe chronic iron overload; showing an up-trend of SF over previous 12 months on single chelator. Secondary Outcome Measures: • The secondary outcome measure is to determine the number of patients who will develop adverse events in order to assess safety upon administering the drugs in combination (DFP and DFX) compared to the combination of DFO and DFP.